THE MECHANISMS OF AUTOIMMUNE RESPONSE INITIATION IN MULTIPLE SCLEROSIS
THE MECHANISMS OF AUTOIMMUNE RESPONSE INITIATION IN MULTIPLE SCLEROSIS
批准号:
7273519
负责人:
Silva Markovic-Plese
金额:
$16.56万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-15 至 2008-07-31
关键词:
AffectAgeAntigen-Presenting CellsAntigensAutoantigensAutoimmune ProcessAutoimmune ResponsesBlood CirculationCD28 geneCD4 Positive T LymphocytesCNS Demyelinating Autoimmune DiseasesCell DeathCellsCharacteristicsChronicComplex MixturesCytokine GeneDevelopmentDiseaseEnvironmentEtiologyEventExhibitsFrequenciesGene ExpressionGoalsGrowthHumanInflammatoryLigandsMolecularMolecular MimicryMultiple SclerosisMyelinMyelin Basic ProteinsNeuraxisNumbersOrganPathogenesisPathologicPathway interactionsPatientsPeptide LibraryPeptidesPeripheralPhysiologicalPlayPliabilityPredispositionPrincipal InvestigatorProliferatingRelapsing-Remitting Multiple SclerosisReportingRoleSelf ToleranceSpecificityT-Cell ActivationT-Cell ReceptorT-LymphocyteTestingViral Genomeautoreactive T cellcentral nervous system demyelinating disordercombinatorialdisabilitydisorder controlinsightnervous system disorderperipheral bloodprogramsresponsetoolyoung adult
中文摘要
描述(由申请人提供):多发性硬化症(MS)是一种中枢神经系统(CNS)的慢性自身免疫性脱髓鞘疾病,主要影响最具生产力年龄的年轻人,因此导致严重残疾。虽然其病因仍然难以捉摸,但大多数证据支持该疾病的自身免疫发病机制。根据这一假设,自身反应性T细胞的激活是MS自身免疫反应发展的中心事件。本研究的目的是检测MS自身免疫反应启动中涉及的分子事件。简并性和分子模拟是一种常见的现象,可能在MS中启动自身免疫反应中发挥作用。开发了偏向的组合肽文库作为表征简并T细胞的工具。由于自身抗原主要是弱TCR配体,我们提出髓鞘反应性T细胞可能在具有退化TCR的细胞中过度表达。与健康对照相比,MS患者中髓鞘碱性蛋白(MBP)特异性T细胞表现出降低的CD28共刺激需求。我们假设,共刺激途径的失调发挥作用的初始激活,延长生存期,并在MS的自身反应性细胞的扩增。共刺激独立的激活可能是特别相关的CNS内的自身抗原识别,因为局部炎症环境增强自身抗原呈递,即使在没有共刺激分子的常驻抗原呈递细胞。我们计划通过追求以下具体目标来实现我们的目标:1)确定具有高度TCR灵活性的T细胞克隆型的频率和TCR库。2)定义RR MS患者和OND对照中具有柔性TCR的T细胞活化和生长特征的共刺激要求。3)确定炎症环境诱导自身反应性T细胞活化的机制。这些研究提供的信息可能会产生重要的见解的生理和病理作用的自身反应性T细胞,并在结构和功能上的MS的新疗法的具体目标。
英文摘要
DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system (CNS) affecting primarily young adults in their most productive age, and therefore causing a significant disability. While its etiology remains elusive, most evidence supports the autoimmune pathogenesis of the disease. According to this hypothesis, the activation of autoreactive T-cells is a central event in the development of autoimmune response in MS. The objective of this proposal is to examine molecular events involved in the initiation of autoimmune response in MS. Recent studies have reported an unexpectedly high degree of T-cell receptor (TCR) degeneracy and molecular mimicry as a frequent phenomenon that might play a role in the initiation of autoimmune response in MS. MHC DR2-biased combinatorial peptide libraries are developed as a tool to characterize degenerate T-cells. As auto-antigens are predominantly weak TCR ligands, we propose that myelin-reactive T-cells may be over-represented among the cells with a degenerate TCR. Myelin basic protein (MBP)-specific T-cells exhibit decreased CD28 co-stimulatory requirements in MS patients when compared to healthy controls. We hypothesize that dysregulation of co-stimulatory pathways play a role in the initial activation, prolonged survival, and the expansion of autoreactive cells in MS. Co-stimulation-independent activation might be particularly relevant for the autoantigen recognition within the CNS, as local inflammatory environment enhances autoantigen presentation even in the absence of co-stimulatory molecules on the resident antigen presenting cells. We plan to achieve our objective by pursuing the following Specific Aims: 1) Determine the frequency and TCR repertoire of T-cell clonotypes with a high degree of TCR flexibility. 2) Define co-stimulation requirements for the activation and growth characteristics of T-cells with flexible TCR in RR MS patients and OND controls. 3) Identify mechanisms by which the inflammatory environment induces the autoreactive T-cell activation. The information provided by these studies may yield important insights into the physiologic and pathologic role of the autoreactive T cells, and characterize structurally and functionally the specific targets for the new therapies of MS.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.
深入了解阿仑单抗治疗多发性硬化症的疗效机制。
DOI:
--
发表时间:
2013
期刊:
Journal of clinical & cellular immunology
影响因子:
--
作者:
[Freedman,MarkS, Kaplan,JohanneM, Markovic-Plese,Silva]
通讯作者:
Markovic-Plese,Silva
DOI:
10.1016/j.clim.2008.08.030
发表时间:
2009-03
期刊:
Clinical immunology (Orlando, Fla.)
影响因子:
--
作者:
[Montes M, Zhang X, Berthelot L, Laplaud DA, Brouard S, Jin J, Rogan S, Armao D, Jewells V, Soulillou JP, Markovic-Plese S]
通讯作者:
Markovic-Plese S
Degenerate T-cell receptor recognition, autoreactive cells, and the autoimmune response in multiple sclerosis.
多发性硬化症中的退化 T 细胞受体识别、自身反应性细胞和自身免疫反应。
DOI:
10.1177/1073858409332404
发表时间:
2009
期刊:
The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry
影响因子:
--
作者:
[Markovic-Plese,Silva]
通讯作者:
Markovic-Plese,Silva
Immunoregulatory effect of microparticle delivered STING agonist in the control of experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS)
-
批准号:10392967
-
项目类别:
-
资助金额:$19.6万
-
财政年份:2021
-
负责人:Silva Markovic-Plese
-
依托单位:
The Role of IL-II in the development of autoimmune response in multiple sclerosis
-
批准号:10221496
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2018
-
负责人:Silva Markovic-Plese
-
依托单位:
The Role of IL-II in the development of autoimmune response in multiple sclerosis
-
批准号:10442499
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2018
-
负责人:Silva Markovic-Plese
-
依托单位:
The Role of IL-11 in Development of Th17-mediated Autoimmune Response in EAE
-
批准号:8693109
-
项目类别:
-
资助金额:$7.6万
-
财政年份:2014
-
负责人:Silva Markovic-Plese
-
依托单位:
THE MECHANISMS OF AUTOIMMUNE RESPONSE INITIATION IN MS
-
批准号:6785871
-
项目类别:
-
资助金额:$16.56万
-
财政年份:2003
-
负责人:Silva Markovic-Plese
-
依托单位:
THE MECHANISMS OF AUTOIMMUNE RESPONSE INITIATION IN MS
-
批准号:7092643
-
项目类别:
-
资助金额:$16.56万
-
财政年份:2003
-
负责人:Silva Markovic-Plese
-
依托单位:
THE MECHANISMS OF AUTOIMMUNE RESPONSE INITIATION IN MS
-
批准号:6602385
-
项目类别:
-
资助金额:$16.56万
-
财政年份:2003
-
负责人:Silva Markovic-Plese
-
依托单位:
THE MECHANISMS OF AUTOIMMUNE RESPONSE INITIATION IN MS
-
批准号:6921316
-
项目类别:
-
资助金额:$16.56万
-
财政年份:2003
-
负责人:Silva Markovic-Plese
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: